5xxy - Revision history

OCA at 08:17, 22 November 2023

OCA — Wed, 22 Nov 2023 08:17:22 GMT

←Older revision		Revision as of 08:17, 22 November 2023
Line 1:		Line 1:

	==Crystal structure of PD-L1 complexed with atezolizumab fab at 2.9A==		==Crystal structure of PD-L1 complexed with atezolizumab fab at 2.9A==
-	<StructureSection load='5xxy' size='340' side='right' caption='[[5xxy]], [[Resolution\|resolution]] 2.90Å' scene=''>	+	<StructureSection load='5xxy' size='340' side='right'caption='[[5xxy]], [[Resolution\|resolution]] 2.90Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[5xxy]] is a 3 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5XXY OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5XXY FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[5xxy]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5XXY OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5XXY FirstGlance]. <br>
-	</td></tr><tr id='~~gene~~'><td class="sblockLbl"><b>[[~~Gene~~\|~~Gene~~:]]</b></td><td class="sblockDat">~~CD274~~, ~~B7H1, PDCD1L1, PDCD1LG1, PDL1 (~~[~~http://www~~.~~ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info~~&~~srchmode=5&id=9606 HUMAN])~~</td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.9Å</td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5xxy FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5xxy OCA], [~~http~~://pdbe.org/5xxy PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=5xxy RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/5xxy PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=5xxy ProSAT]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5xxy FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5xxy OCA], [https://pdbe.org/5xxy PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5xxy RCSB], [https://www.ebi.ac.uk/pdbsum/5xxy PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5xxy ProSAT]</span></td></tr>
	</table>		</table>
	== Function ==		== Function ==
-	[~~[http~~://www.uniprot.org/uniprot/PD1L1_HUMAN PD1L1_HUMAN]] Involved in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation and cytokine production.<ref>PMID:10581077</ref> <ref>PMID:11015443</ref>	+	[https://www.uniprot.org/uniprot/PD1L1_HUMAN PD1L1_HUMAN] Involved in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation and cytokine production.<ref>PMID:10581077</ref> <ref>PMID:11015443</ref>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 22:		Line 22:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Human~~]]	+	[[Category: Homo sapiens]]
-	[[Category: ~~Zhang, F~~]]	+	[[Category: Large Structures]]
-	[[Category: ~~Zhou, A~~]]	+	[[Category: Zhang F]]
-	[[Category: ~~Atezolizumab]]~~	+	[[Category: Zhou A]]
-	~~[[Category: Immune system]]~~	+
-	~~[[Category: Pd-l1~~]]	+

OCA at 14:12, 11 April 2018

OCA — Wed, 11 Apr 2018 14:12:21 GMT

←Older revision		Revision as of 14:12, 11 April 2018
Line 9:		Line 9:
	== Function ==		== Function ==
	[[http://www.uniprot.org/uniprot/PD1L1_HUMAN PD1L1_HUMAN]] Involved in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation and cytokine production.<ref>PMID:10581077</ref> <ref>PMID:11015443</ref>		[[http://www.uniprot.org/uniprot/PD1L1_HUMAN PD1L1_HUMAN]] Involved in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation and cytokine production.<ref>PMID:10581077</ref> <ref>PMID:11015443</ref>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Monoclonal antibodies targeting PD-1/PD-L1 signaling pathway have achieved unprecedented success in cancer treatment over the last few years. Atezolizumab is the first PD-L1 monoclonal antibody approved by US FDA for cancer therapy; however the molecular basis of atezolizumab in blocking PD-1/PD-L1 interaction is not fully understood. Here we have solved the crystal structure of PD-L1/atezolizumab complex at 2.9 angstrom resolution. The structure shows that atezolizumab binds the front beta-sheet of PD-L1 through three CDR loops from the heavy chain and one CDR loop from the light chain. The binding involves extensive hydrogen-bonding and hydrophobic interactions. Notably there are multiple aromatic residues from the CDR loops forming Pi-Pi stacking or cation-Pi interactions within the center of the binding interface and the buried surface area is more than 2000 A(2), which is the largest amongst all the known PD-L1/antibody structures. Mutagenesis study revealed that two hot-spot residues (E58, R113) of PD-L1 contribute significantly to the binding of atezolizumab. The structure also shows that atezolizumab binds PD-L1 with a distinct heavy and light chain orientation and it blocks PD-1/PD-L1 interaction through competing with PD-1 for the same PD-L1 surface area. Taken together, the complex structure of PD-L1/atezolizumab solved here revealed the molecular mechanism of atezolizumab in immunotherapy and provides basis for future monoclonal antibody optimization and rational design of small chemical compounds targeting PD-L1 surface.
		+
		+	Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab.,Zhang F, Qi X, Wang X, Wei D, Wu J, Feng L, Cai H, Wang Y, Zeng N, Xu T, Zhou A, Zheng Y Oncotarget. 2017 Oct 6;8(52):90215-90224. doi: 10.18632/oncotarget.21652., eCollection 2017 Oct 27. PMID:29163822<ref>PMID:29163822</ref>
		+
		+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
		+	</div>
		+	<div class="pdbe-citations 5xxy" style="background-color:#fffaf0;"></div>
	== References ==		== References ==
	<references/>		<references/>

OCA at 07:42, 29 November 2017

OCA — Wed, 29 Nov 2017 07:42:02 GMT

←Older revision		Revision as of 07:42, 29 November 2017
Line 1:		Line 1:

-	==~~Complex~~ structure of PD-L1 with atezolizumab ~~Fab~~==	+	==Crystal structure of PD-L1 complexed with atezolizumab fab at 2.9A==
	<StructureSection load='5xxy' size='340' side='right' caption='[[5xxy]], [[Resolution\|resolution]] 2.90Å' scene=''>		<StructureSection load='5xxy' size='340' side='right' caption='[[5xxy]], [[Resolution\|resolution]] 2.90Å' scene=''>
	== Structural highlights ==		== Structural highlights ==

OCA: Protected "5xxy" [edit=sysop:move=sysop]

OCA — Wed, 15 Nov 2017 14:34:17 GMT

Protected "5xxy" [edit=sysop:move=sysop]

←Older revision

Revision as of 14:34, 15 November 2017

OCA: New page: ==Complex structure of PD-L1 with atezolizumab Fab== == Structura...

OCA — Wed, 15 Nov 2017 14:34:16 GMT

New page: ==Complex structure of PD-L1 with atezolizumab Fab== <StructureSection load='5xxy' size='340' side='right' caption='5xxy, resolution 2.90Å' scene=''> == Structura...

New page

==Complex structure of PD-L1 with atezolizumab Fab==
<StructureSection load='5xxy' size='340' side='right' caption='[[5xxy]], [[Resolution|resolution]] 2.90Å' scene=''>
== Structural highlights ==
<table><tr><td colspan='2'>[[5xxy]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5XXY OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5XXY FirstGlance]. <br>
</td></tr><tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5xxy FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5xxy OCA], [http://pdbe.org/5xxy PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5xxy RCSB], [http://www.ebi.ac.uk/pdbsum/5xxy PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5xxy ProSAT]</span></td></tr>
</table>
== Function ==
[[http://www.uniprot.org/uniprot/PD1L1_HUMAN PD1L1_HUMAN]] Involved in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation and cytokine production.<ref>PMID:10581077</ref> <ref>PMID:11015443</ref>
== References ==
<references/>
__TOC__
</StructureSection>
[[Category: Human]]
[[Category: Zhang, F]]
[[Category: Zhou, A]]
[[Category: Atezolizumab]]
[[Category: Immune system]]
[[Category: Pd-l1]]